Xingji Biopharma
星济生物
Xingji Biopharma
Biotech/Healthcare
Xingji Biopharma is dedicated to developing macromolecular anti-infective drugs and currently has six R&D pipelines covering Gram-positive bacteria, Gram-negative bacteria, fungi, and viruses. Two innovative drug pipelines will file IND applications in the near term and begin clinical studies…
Latest round: Series B (2025)
Source: ChinaBulls — chinabulls.com
Last updated 2025-03-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.